A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) is a phase 2 interventional study registered as NCT06961006 by Merck Sharp & Dohme LLC, with 160 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-07-22. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Malignant Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Shares Merck & Co. (MSD), Melanoma, Pembrolizumab.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN
Shares Intismeran autogene, Melanoma, Pembrolizumab.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.
- TrialA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Shares Merck & Co. (MSD), Melanoma, Pembrolizumab.
- TrialA Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Intismeran autogene, Merck & Co. (MSD), Pembrolizumab.